Breakthrough & Progress of Non-small cell lung cancer drug , are you ready?
- Research progress of NSCLC targeted drugs
- Research progress of immune checkpoint inhibitors in NSCLC
- Overview of the 3rd/4th line treatment of advanced NSCLC
- Global & Chinese NSCLC therapeutic area competitive landscape
- An innovative biotech roadshow
Event details
|
DATE Wednesday, Oct 25, 2023 VENUE Online Webex / Zoom TIME 10:00 – 11:00 Berlin time (CET) 16:00 – 17:00 Beijing time (GMT+8) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by Oct 24, 2023 |
PRESENTERS Lingling Cao, CEO & Founder Zhang Ran, Medical advisor REGISTER +86 21 5386 3003 BD@lingmed.net |
Agenda
| CET 10:00 - 10:30 | Breakthrough & Progress of Non-small cell lung cancer drug |
by Zhang Ran (Chinese) |
| CET 10:30 - 10:35 | Linkedbio services & projects introduction | by Lingling Cao (English) |
| CET 10:35 - 10:55 | An innovative biotech roadshow | by Guest speaker (English) |
| CET 10:55 – 11:00 | Q&A | (English & Chinese) |
Presenters
 |
Zhang Ran Medical advisor China Pharmaceutical University master HealthShare Management and Consulting Co., Ltd Co-founder 20 years of experience in new drug development. Engaged in new drug research and development in Yangtze River Pharmaceutical Group、Beijing Kawin Technology Share-Holding Co., Ltd.、Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. Co-founded HealthShare in 2016. Serve a number of listed pharmaceutical enterprises. Mainly engaged in research and development pipeline strategic planning, new drug project evaluation, research and development management. |
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |